Physician profile
David Thornsberry
NPI 1982889135
$4,358.54
in general payments reported to CMS, 2019-2025
25 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $776 · 2022: $1,104 · 2023: $649 · 2024: $708 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.68 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $665.07 | 2022-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $552.60 | 2021-2025 | |
| Lilly USA, LLC | $414.25 | 2021-2024 | Olumiant, Taltz |
| Incyte Corporation | $349.17 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $319.50 | 2021-2025 | Anzupgo, Adbry |
| Abbvie INC. | $304.00 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $230.66 | 2022-2025 | |
| Journey Medical Corporation | $217.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $200.62 | 2021-2025 | |
| Genzyme Corporation | $178.93 | 2021-2025 | |
| Ucb, INC. | $166.96 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $128.99 | 2021-2023 | Targretin |
| Regeneron Healthcare Solutions, INC. | $104.70 | 2022-2025 | Dupixent |
| Amgen INC. | $95.38 | 2023-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $85.70 | 2021-2025 | Tremfya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $81.43 | 2021 | |
| Epi Health, LLC | $60.83 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.39 | 2022-2023 | Spevigo |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Almirall LLC | $27.67 | 2024 | Klisyri |
| Sanofi-Aventis U.S. LLC | $24.90 | 2021 | |
| Vyne Pharmaceuticals INC. | $22.13 | 2021 | |
| Botanix Sb INC | $15.56 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $15.33 | 2023 | Vtama |
| Genentech USA, INC. | $5.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Thornsberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.